Trial reportLeukemia2017
High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).
Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06830421 (Age-adjusted High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation or Conventional Chemotherapy With R-MP as First-line Treatment in Elderly Primary CNS Lymphoma Patients - a Randomized Phase III Trial), which is not on this map. Cited by 78 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 1 pooled it
9.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Age-adjusted High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation or Conventional Chemotherapy With R-MP as First-line Treatment in Elderly Primary CNS Lymphoma Patients - a Randomized Phase III Trial
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it, 181 citations in OpenAlex.
- Pooled it
- Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.Journal of hematology & oncology · 2024Trial
- Trial
- MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma.Journal of neuro-oncology · 2021Trial
- Advances in molecular pathobiology of PCNSL - towards clinical implementation of novel diagnostics and therapeutics.Biomarker research · 2026Review
- Primary central nervous system lymphoma-current standards and recent developments.Neuro-oncology practice · 2026Review
- Translating advances in primary central nervous system lymphoma: from prognostic stratification to treatment innovation.Frontiers in oncology · 2026Review
- Cumulative pre-chemoimmunotherapy dexamethasone dose is associated with adverse outcomes in primary central nervous system lymphoma.Frontiers in oncology · 2026Article
- Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi Era.International journal of molecular sciences · 2025Review
- Lenalidomide-rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach.Annals of hematology · 2025Article
- Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma.Blood neoplasia · 2025Article
- Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma.Haematologica · 2025Article
- Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas.Bone marrow transplantation · 2025Review
- Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience.Blood advances · 2025Article
- Consensus on managing delayed methotrexate elimination in high-dose therapy: insights from the Middle East.Frontiers in oncology · 2025Review
- Both consolidation and maintenance treatment improve outcomes in primary central nervous system lymphoma: real-world evidence from a tertiary medical center.Journal of Cancer · 2025Article
- Review
- Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020.Neuro-oncology · 2024Article
- Diagnostics and treatment delay in primary central nervous system lymphoma: What the neurosurgeon should know.Acta neurochirurgica · 2024Review
- Clinical outcomes of etoposide and cytarabine as consolidation in elderly patients with primary CNS lymphoma.The oncologist · 2024Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 20 institutions in 2 countries.
K FritschDepartment of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany.
B KasendaDepartment of Haematology/Oncology, Klinikum Stuttgart, Stuttgart, Germany.
E SchorbDepartment of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany.
P HauDepartment of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg, Regensburg, Germany.
J BloehdornDepartment of Internal Medicine III, University of Ulm, Ulm, Germany.
R MöhleDepartment of Medicine II, Hematology and Oncology, University of Tübingen, Tübingen, Germany.
S LöwDepartment of Neurology, University Hospital Heidelberg, Heidelberg, Germany.
M BinderDepartment of Internal Medicine II, Oncology/Hematology/Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
J AttaDepartment of Internal Medicine II, Center of Internal Medicine, Johann Wolfgang Goethe-University, Frankfurt, Germany.
U KellerIII Medical Department, Technische Universität München, Munich, Germany.
H-H WolfDepartment of Haematology and Oncology, University Hospital Halle, Halle, Germany.
S W KrauseDepartment of Internal Medicine 5, Universitätsklinik Erlangen, Erlangen, Germany.
G HeßDepartment of Hematology/Oncology, Johannes Gutenberg University, Mainz, Germany.
R NaumannDepartment of Internal Medicine, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany.
S SasseDepartment of Internal Medicine I, University Hospital of Cologne, Cologne, Germany.
C HirtDepartment of Internal Medicine C (Haematology and Oncology, Marrow Transplantation), Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany.
M LamprechtDepartment of Internal Medicine II, University Hospital of Schleswig-Holstein, Kiel, Germany.
U MartensDepartment of Hematology/Oncology, Cancer Center Heilbronn-Franken, Heilbronn, Germany.
A MorgnerDepartment of Internal Medicine III, Klinikum Chemnitz GmbH, Chemnitz, Germany.
J PanseDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
N FrickhofenDepartment of Hematology and Oncology, HELIOS Dr-Horst-Schmidt-Kliniken, Wiesbaden, Germany.
A RöthDepartment of Haematology, West German Cancer Centre, University Hospital Essen, Essen, Germany.
C HaderDepartment of Neuro-Radiology, University Hospital Freiburg, Freiburg, Germany.
M DeckertInstitute of Neuropathology, University Hospital of Cologne, Cologne, Germany.
H FrickerDepartment of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany.
G IhorstClinical Trials Unit, Medical Centre - University of Freiburg, Freiburg, Germany.
J FinkeDepartment of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany.
G IllerhausDepartment of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany.
University Medical Center Freiburg · DEKlinikum Stuttgart · DEUniversity Hospital Cologne · DEEssen University Hospital · DEGemeinschaftsklinikum Mittelrhein · DEGoethe University Frankfurt · DEHelios Dr. Horst Schmidt Kliniken Wiesbaden · DEJohannes Gutenberg University Mainz · DEKlinikum Chemnitz · DERWTH Aachen University · DETechnical University of Munich · DEUniversität Greifswald · DEUniversitätsklinikum Erlangen · DEUniversität Ulm · DEUniversity Hospital Heidelberg · DEUniversity Hospital in Halle · DEUniversity Hospital Regensburg · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversity of Freiburg · DEUniversity of Lübeck · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate immuno-chemotherapy for elderly immuno-competent patients (⩾65 years) with newly diagnosed primary central nervous system lymphoma, we conducted a multicentre single-arm trial. One cycle consisted of rituximab (375 mg/m
Indexed as
AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsFemaleHumansImmunologic FactorsLymphomaMaleMethotrexateNeoplasm StagingProportional Hazards ModelsQuality of LifeRemission InductionTreatment OutcomeTumor BurdenImmunologic FactorsMethotrexate
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT06830421ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.